Alpha-lipoic acid effects on coronary heart disease
Phase 3
- Conditions
- Coronary Heart Disease.Chronic ischemic heart disease, unspecified
- Registration Number
- IRCT20170513033941N48
- Lead Sponsor
- Kashan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Patients aged 45-85 years
People diagnosed with type 2 diabetes and coronary heart disease.
Exclusion Criteria
Patients with thyroid disorders.
Severe renal insufficiency
hepatic failure
Those experiencing an acute myocardial infarction within the past 3 months
Patients undergoing cardiac surgery within the past 3 months
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Insulin resistance. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Calculation using homeostasis model of assessment insulin resistance formula.;Fasting serum Insulin levels. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.
- Secondary Outcome Measures
Name Time Method Total cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;High-density lipoprotein (HDL) cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;High-sensitivity C-reactive protein (hs-CRP). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.